Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

The Children s Medical Center Corporation patents


Recent patent applications related to The Children s Medical Center Corporation. The Children s Medical Center Corporation is listed as an Agent/Assignee. Note: The Children s Medical Center Corporation may have other listings under different names/spellings. We're not affiliated with The Children s Medical Center Corporation, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "T" | The Children s Medical Center Corporation-related inventors


Therapeutic target for the treatment of cancers and related therapies and methods

Disclosed herein are compositions and methods for treating or preventing certain cancers in a subject. In certain embodiments such compositions and methods generally relate to the use of G-coupled protein receptor 40 (GPR40) agonists to inhibit the growth or induce apoptosis of certain cancer cells. The compositions and related methods... The Children s Medical Center Corporation

Non-toxic topical anesthetic ophthalmic compositions

Compositions and methods for prolonging the local anesthetic effect of site 1 sodium channel blockers and local anesthetics with minimal or reduced toxicity have been developed for ophthalmic use. It has been established that agents such as dexmedetomidine having alpha-2-adrenergic agonist and Hyperpolarization-activated cyclic nucleotide-gated channel antagonist activity can dramatically... The Children s Medical Center Corporation

Methods and compositions for promoting glucose homeostasis

A method of reducing blood glucose in a subject has been developed. In preferred embodiments, the method involves administering to the subject a specific activator of endogenous mitogen-activated protein kinase kinase 6 (MKK3), mitogen-activated protein kinase kinase 6 (MKK4), mitogen-activated protein kinase kinase 6 (MKK6), p38 mitogen-activated protein kinase (p38MAPK),... The Children s Medical Center Corporation

Biocompatible coatings and hydrogels for reducing foreign body response and fibrosis

Zwitterionic polymers or biocompatible polymers with improved properties for cell encapsulation, coating of devices, or a combination thereof are described. The biocompatible polymer contains a zwitterionic monomer, a monomer with a reactive side chain, and optionally another hydrophobic monomer or a neutral hydrophilic monomer. The zwitterionic polymers are cross-linked with... The Children s Medical Center Corporation

Sustained and reversible oral drug delivery systems

A composition that achieves sustained oral drug release is provided. The composition includes liposomes, micelles, or polymeric particles, for example, having a hydrophobic core and an amphipathic corona, wherein the core contains a therapeutic, diagnostic, nutraceutical, cosmeceutical or prophylactic agent to be released, and the corona has targeting ligands immobilized... The Children s Medical Center Corporation

Compounds for the treatment of obesity and methods of use thereof

Pentacyclic triterpene weight loss agents are provided herein. Also provided are pharmaceutical formulations containing a therapeutically effective amount of one or more of the weight loss agents, or pharmaceutically acceptable salts or prodrugs thereof, in combination with one or more pharmaceutically acceptable excipients. The pharmaceutical formulations can be administered to... The Children s Medical Center Corporation

Materials with improved properties

Products, such as devices, prostheses, and materials, whose surfaces have been modified in order to impart beneficial properties to these products are disclosed. The surface-modified products have improved biocompatibility compared to a corresponding product that lacks the modification. Following implantation in a subject, the surface-modified products induce a lower foreign-body... The Children s Medical Center Corporation

Modified alginates for anti-fibrotic materials and applications

Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical... The Children s Medical Center Corporation

Modified alginates for anti-fibrotic materials and applications

Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical... The Children s Medical Center Corporation

Selective oxidation of 5-methylcytosine by tet-family proteins

The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes... The Children s Medical Center Corporation

Selective oxidation of 5-methylcytosine by tet-family proteins

The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes... The Children s Medical Center Corporation

Hsp90 inhibitors for the treatment of obesity and methods of use thereof

HSP 90 inhibitors for the promotion of weight loss, as well as formulations containing these inhibitors and methods of using thereof, are described herein. Also provided are pharmaceutical compositions containing a therapeutically effective amount of a weight loss agent, or a pharmaceutically acceptable salt or prodrug thereof, in combination with... The Children s Medical Center Corporation

Modified integrin polypeptides, modified integrin polypeptide dimers, and uses thereof

Described herein are modified integrin α and/or β headpiece polypeptides, and crystallizable integrin polypeptide dimers comprising a modified integrin α and/or β headpiece polypeptide and a disulfide bond linking the two integrin headpiece polypeptide subunits. Methods for using the modified integrin α and/or β headpiece polypeptides and the integrin polypeptide... The Children s Medical Center Corporation

Selective oxidation of 5-methylcytosine by tet-family proteins

The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes... The Children s Medical Center Corporation

Selective oxidation of 5-methylcytosine by tet-family proteins

The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes... The Children s Medical Center Corporation

Selective oxidation of 5-methylcytosine by tet-family proteins

The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes... The Children s Medical Center Corporation

Selective oxidation of 5-methylcytosine by tet-family proteins

The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes... The Children s Medical Center Corporation

Compositions and methods for treating diabetes

Compositions containing an FKBP 11 peptide (i.e., FKBP11 polypeptide, a variant or a fragment thereof), a fusion protein containing an FKBP11 peptide, or a nucleic acid encoding an FKBP 11 peptide are disclosed. Also disclosed are methods of reducing blood glucose levels, improving glucose tolerance, decreasing hepatic gluconeogenic activity and/or... The Children s Medical Center Corporation

Multi-layer hydrogel capsules for encapsulation of cells and cell aggregates

Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount... The Children s Medical Center Corporation








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with The Children s Medical Center Corporation in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for The Children s Medical Center Corporation with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###